<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 | 极客快訊</title><meta property="og:title" content="中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p9.pstatp.com/large/pgc-image/SDysdQx2x7bjFj"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/1f4a5d55.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/1f4a5d55.html><meta property="article:published_time" content="2020-11-14T20:51:30+08:00"><meta property="article:modified_time" content="2020-11-14T20:51:30+08:00"><meta name=Keywords content><meta name=description content="中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物"><meta name=author content="极客快訊"><meta property="og:url" content="/cn/%E7%A7%91%E5%AD%A6/1f4a5d55.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快讯 Geek Bank</a></h1><p class=description>为你带来最全的科技知识 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E5%AD%A6.html>科学</a></span></div><div class=post-content><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/SDysdQx2x7bjFj><p>免疫检查点抑制剂（ICI）在头颈部鳞癌( HNSCC)中的疗效已得到证实。但是，ICI治疗的主要局限性在于其总体有效率较低和自付费用高。所以我们迫切需要全面了解HNSCC的肿瘤微环境，识别潜在的免疫治疗疗效和预后判断的生物标志物，有助于实现HNSCC患者的个体化免疫治疗。</p><p>近日，中山大学附属肿瘤医院孙颖、周冠群教授团队在Clinical Cancer Research上发表的一项研究表明，基于SFRP4、CPXM1和COL5A1基因构建的免疫相关基因预后指数（IRGPI）是判断HNSCC患者预后和免疫治疗获益的有前景的生物标志物。</p><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/SEcPHQ7Am5nDKz><p>该研究基于癌症基因组图谱（TCGA）HNSCC免疫数据库（n = 546），通过加权基因共表达网络分析（WGCNA）确定了22个与免疫相关的关键基因。利用多因素Cox回归分析筛选出三个基因（SFRP4、CPXM1和COL5A1），构建了IRGPI，并使用基因表达综合数据库（GEO）进行了验证（n = 270）。随后研究人员分析了IRGPI定义的不同亚组中ICI治疗后的获益情况以及分子和免疫学特征。</p><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPHRbJJs7KWm><p class=pgc-img-caption>图1 关键基因</p><p>结果发现，相比于IRGPI评分低的患者，高IRGPI患者总生存（OS）显著延长，与GEO队列结果一致。此外，高 IRGPI与DNA修复相关通路，TP53低突变率，CD8 T细胞、CD4 T细胞和M1巨噬细胞高浸润，主动免疫和侵袭性表型较少有关，并且可从ICI治疗中获益更多。</p><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPHSb4PwPdPy><p class=pgc-img-caption>图2 IRGPI评分与OS</p><p>相反，低IRGPI与肿瘤和转移相关通路，TP53和PIK3CA高突变率，B细胞、M0巨噬细胞和M2巨噬细胞高浸润，免疫抑制和更具侵袭性表型相关，且从ICI治疗中获益较少。</p><p>这一结果表明，IRGPI是区分HNSCC患者预后、分子和免疫特征以及免疫疗法获益的有前景的生物标志物，当然结果还需要进一步研究论证。</p><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPHT06N3KvD2><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPI90mjtiyO><p>图3 图文摘要</p><p>参考文献：</p><p>An immune-related gene prognostic index for head and neck squamous cell carcinoma.Clinical Cancer Research.DOI: 10.1158/1078-0432.CCR-20-2166.</p><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/S6E1PmvAUqo9RC><section class=colorful-content style=display:none><div><div class=tt_format_content id=js_content><section style=box-sizing:border-box><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><section style=max-width:100%;vertical-align:middle;display:inline-block;line-height:0;box-sizing:border-box><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/SDysdQx2x7bjFj></section></section><section powered-by=xiumi.us style="font-size:16px;margin:10px 0%;box-sizing:border-box"><section style=display:inline-block;width:100%;vertical-align:top;background-color:#f3f3f3;box-sizing:border-box><section powered-by=xiumi.us style=box-sizing:border-box><section style="display:flex;flex-flow:row nowrap;transform:translate3d(3px,0px,0px);-webkit-transform:translate3d(3px,0px,0px);-moz-transform:translate3d(3px,0px,0px);-o-transform:translate3d(3px,0px,0px);margin:3px 0% -3px;box-sizing:border-box"><section style="display:inline-block;vertical-align:bottom;width:auto;min-width:10%;max-width:100%;flex:0 0 auto;height:auto;align-self:flex-end;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:left;justify-content:flex-start;margin-right:0%;margin-bottom:-25px;margin-left:0%;box-sizing:border-box><section style="display:inline-block;width:50px;height:30px;vertical-align:top;overflow:hidden;box-shadow:#0000 0 0;border-style:solid;border-width:5px;border-radius:0;border-color:#1980datransparenttransparent#1980da;box-sizing:border-box"><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section><section style="display:inline-block;vertical-align:bottom;width:auto;align-self:flex-end;flex:0 0 0%;height:auto;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:center;font-size:0;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=display:inline-block;width:0;height:0;vertical-align:top;overflow:hidden;border-width:3px;border-radius:0;border-style:solid;border-color:transparent#1980da#1980datransparent;box-sizing:border-box><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section><section style="display:inline-block;vertical-align:bottom;width:auto;align-self:flex-end;flex:0 0 0%;height:auto;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:center;font-size:0;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=display:inline-block;width:0;height:0;vertical-align:top;overflow:hidden;border-width:3px;border-radius:0;border-style:solid;border-color:#1980datransparenttransparent#1980da;box-sizing:border-box><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section><section style="display:inline-block;vertical-align:bottom;width:auto;align-self:flex-end;flex:0 0 0%;height:auto;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:center;font-size:0;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=display:inline-block;width:0;height:0;vertical-align:top;overflow:hidden;border-width:3px;border-radius:0;border-style:solid;border-color:transparent#1980da#1980datransparent;box-sizing:border-box><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section><section style="display:inline-block;vertical-align:bottom;width:auto;align-self:flex-end;flex:0 0 0%;height:auto;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:center;font-size:0;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=display:inline-block;width:0;height:0;vertical-align:top;overflow:hidden;border-width:3px;border-radius:0;border-style:solid;border-color:#1980datransparenttransparent#1980da;box-sizing:border-box><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section><section style="display:inline-block;vertical-align:bottom;width:auto;align-self:flex-end;flex:0 0 0%;height:auto;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:center;font-size:0;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=display:inline-block;width:0;height:0;vertical-align:top;overflow:hidden;border-width:3px;border-radius:0;border-style:solid;border-color:transparent#1980da#1980datransparent;box-sizing:border-box><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section><section style="display:inline-block;vertical-align:bottom;width:auto;align-self:flex-end;flex:0 0 0%;height:auto;box-sizing:border-box"><section powered-by=xiumi.us style=text-align:center;font-size:0;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=display:inline-block;width:0;height:0;vertical-align:top;overflow:hidden;border-width:3px;border-radius:0;border-style:solid;border-color:#1980datransparenttransparent#1980da;box-sizing:border-box><section><svg style="float:left;line-height:0;width:0;vertical-align:top" viewbox="0 0 1 1"/></section></section></section></section></section></section><section powered-by=xiumi.us style=box-sizing:border-box><section style="display:flex;flex-flow:row nowrap;margin-right:0%;margin-bottom:5px;margin-left:0%;box-sizing:border-box"><section style="display:inline-block;width:auto;vertical-align:top;background-color:#fff;flex:100 100 0%;align-self:flex-start;height:auto;margin-right:5px;margin-left:5px;border-width:1px;border-radius:0;border-style:solid;border-color:#1980da;padding:15px 20px;box-sizing:border-box"><section powered-by=xiumi.us style=opacity:.99;margin-right:0%;margin-left:0%;box-sizing:border-box><section style=font-size:15px;letter-spacing:1.5px;line-height:1.8;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box>免疫检查点抑制剂（ICI）在头颈部鳞癌( HNSCC)中的疗效已得到证实。但是，ICI治疗的主要局限性在于其总体有效率较低和自付费用高。所以我们迫切需要全面了解HNSCC的肿瘤微环境，识别潜在的免疫治疗疗效和预后判断的生物标志物，有助于实现HNSCC患者的个体化免疫治疗。</p></section></section></section></section></section></section></section><section powered-by=xiumi.us style=font-size:16px;padding-right:8px;padding-left:8px;letter-spacing:1px;line-height:1.7;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box><br style=box-sizing:border-box></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box>近日，中山大学附属肿瘤医院孙颖、周冠群教授团队在Clinical Cancer Research上发表的一项研究表明，基于SFRP4、CPXM1和COL5A1基因构建的免疫相关基因预后指数（IRGPI）是判断HNSCC患者预后和免疫治疗获益的有前景的生物标志物。<br style=box-sizing:border-box></span></p><p style=white-space:normal;box-sizing:border-box><br style=box-sizing:border-box></p></section><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><section style=max-width:100%;vertical-align:middle;display:inline-block;line-height:0;box-sizing:border-box><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/SEcPHQ7Am5nDKz></section></section><section powered-by=xiumi.us style=font-size:16px;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box><br style=box-sizing:border-box></p></section><section powered-by=xiumi.us style=font-size:16px;padding-right:8px;padding-left:8px;letter-spacing:1px;line-height:1.75;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box>该研究基于癌症基因组图谱（TCGA）HNSCC免疫数据库（n = 546），通过加权基因共表达网络分析（WGCNA）确定了22个与免疫相关的关键基因。利用多因素Cox回归分析筛选出三个基因（SFRP4、CPXM1和COL5A1），构建了IRGPI，并使用基因表达综合数据库（GEO）进行了验证（n = 270）。随后研究人员分析了IRGPI定义的不同亚组中ICI治疗后的获益情况以及分子和免疫学特征。</span></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box></span></p></section><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><section style=max-width:100%;vertical-align:middle;display:inline-block;line-height:0;box-sizing:border-box><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPHRbJJs7KWm></section></section><section powered-by=xiumi.us style=font-size:16px;padding-right:8px;padding-left:8px;letter-spacing:1px;line-height:1.75;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box;text-align:center><span style=box-sizing:border-box;font-size:12px>图1 关键基因</span></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box><br></span></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box>结果发现，相比于IRGPI评分低的患者，高IRGPI患者总生存（OS）显著延长，与GEO队列结果一致。此外，高 IRGPI与DNA修复相关通路，TP53低突变率，CD8 T细胞、CD4 T细胞和M1巨噬细胞高浸润，主动免疫和侵袭性表型较少有关，并且可从ICI治疗中获益更多。</span></p><p style=white-space:normal;box-sizing:border-box><br></p></section><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><section style=max-width:100%;vertical-align:middle;display:inline-block;line-height:0;box-sizing:border-box><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPHSb4PwPdPy></section></section><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><span style=font-size:12px>图2 <span style=font-size:12px;letter-spacing:1px>IRGPI</span>评分与OS</span><br></section><section powered-by=xiumi.us style=font-size:16px;padding-right:8px;padding-left:8px;letter-spacing:1px;line-height:1.75;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box><br></span></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box>相反，低IRGPI与肿瘤和转移相关通路，TP53和PIK3CA高突变率，B细胞、M0巨噬细胞和M2巨噬细胞高浸润，免疫抑制和更具侵袭性表型相关，且从ICI治疗中获益较少。</span><br style=box-sizing:border-box></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box></span></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box>这一结果表明，IRGPI是区分HNSCC患者预后、分子和免疫特征以及免疫疗法获益的有前景的生物标志物，当然结果还需要进一步研究论证。</span></p><p style=white-space:normal;box-sizing:border-box><span style=font-size:15px;box-sizing:border-box><br></span></p><p style=text-align:center><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPHT06N3KvD2></p></section><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><section style=max-width:100%;vertical-align:middle;display:inline-block;line-height:0;box-sizing:border-box><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/SEcPI90mjtiyO></section></section><section powered-by=xiumi.us style=padding-right:8px;padding-left:8px;letter-spacing:1px;line-height:1.75;box-sizing:border-box><p style=white-space:normal;box-sizing:border-box;text-align:center><span style=font-size:12px>图3 </span><span style=font-size:12px>图文摘要</span></p><p style=font-size:16px;white-space:normal;box-sizing:border-box><br></p></section><section powered-by=xiumi.us style=font-size:16px;padding-right:8px;padding-left:8px;box-sizing:border-box><p style=text-align:left;box-sizing:border-box><span style=font-size:12px;color:#85888a;box-sizing:border-box>参考文献：</span></p><p style=text-align:left;box-sizing:border-box><span style=font-size:12px;color:#85888a;box-sizing:border-box>An immune-related gene prognostic index for head and neck squamous cell carcinoma.Clinical Cancer Research.DOI: 10.1158/1078-0432.CCR-20-2166.</span></p><p style=box-sizing:border-box><br style=box-sizing:border-box></p></section><section powered-by=xiumi.us style=font-size:16px;text-align:center;margin-top:10px;margin-bottom:10px;box-sizing:border-box><section style=max-width:100%;vertical-align:middle;display:inline-block;line-height:0;box-sizing:border-box><img alt=中山大学附属肿瘤医院孙颖、周冠群教授团队：IRGPI可能是HNSCC患者免疫治疗潜在的生物标志物 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/S6E1PmvAUqo9RC></section></section></section><p><br></p></div></div></section></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'大学','附属','肿瘤'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>